DNA-dependent protein kinase regulated glioblastoma survival in doxorubicin-induced cytotoxicity

Genomic Medicine, Biomarkers, and Health Sciences

Volumn 4, Issue 1-2, 2012, Pages 54-56

  Lin, Li Hsun ^a   Chan, Hong Lin ^a   Chou, Hsiu Chuan ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Cytotoxicity; DNA PK; Doxorubicin; Drug resistant

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN;

ARTICLE; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CYTOTOXICITY; FUNCTIONAL PROTEOMICS; GLIOBLASTOMA; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84861574138     PISSN: 22114254     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gmbhs.2012.04.007     Document Type: Article

References (2)

1. Davidson D, Grenier J, Martinez-Marignac V, et al. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest New Drugs. 2011 May 13. [Epub ahead of print, 2011]. doi:10.1007/s10637-011-9678-5.
2. Friesen C., Uhl M., Pannicke U., et al. DNA-ligase IV and DNA-protein kinase play a critical role in deficient caspases activation in apoptosis-resistant cancer cells by using doxorubicin. Mol Biol Cell 2008, 19:3283-3289.